Monoclonal gammapathy of renal significance (MGRS) at the current state: terminology, diagnosis and treatment

Cover Page

Abstract


In this article we discussed the current state of monoclonal gammapathy of renal significance (Monoclonal Gammopathy of Renal Significance – MGRS) and revealed problems of B-cell clone secreting nephrotoxic monoclonal immunoglobulin identification. We followed 276 patients with monoclonal gammapathy including patients with non-amyloid nephropathy. The majority of patients had systemic AL-amyloidosis. We established better survival of the treated patients with systemic AL-amyloidosis in comparison with retrospective untreated cohort. We considered current treatment of patients with non-amyloid nephropathy and focused on the crucial role of multidisciplinary approach in management of these patients.


Full Text

Restricted Access

About the authors

Lidia V. Lysenko (Kozlovskaya)

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: lidia.v.lysenko@gmail.com
ORCID iD: 0000-0002-1166-7308

Russian Federation, Moscow

проф. каф. внутренних, профессиональных болезней и ревматологии

Vilen V. Rameev

Sechenov First Moscow State Medical University (Sechenov University)

Email: lidia.v.lysenko@gmail.com
ORCID iD: 0000-0003-4260-0226

Russian Federation, Moscow

доц. каф. внутренних, профессиональных болезней и ревматологии

Tatyana V. Androsova

Sechenov First Moscow State Medical University (Sechenov University)

Email: lidia.v.lysenko@gmail.com
ORCID iD: 0000-0002-9951-126X

Russian Federation, Moscow

ассистент каф. внутренних, профессиональных болезней и ревматологии

References

  1. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: Diagnosis and treatment. Mayo Clin Proc. 2006;81(5):693-703. doi: 10.4065/81.5.693
  2. Fermand JP, Bridoux F, Dispenzieri A, et al. Monoclonal gammopathy of clinical significance: A novel concept with therapeutic implications. Blood. 2018;132(14):1478-85. doi: 10.1182/blood-2018-04-839480
  3. Zingone A, Kuehl WM. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol. 2011;48(1):4-12. doi: 10.1053/j.seminhematol.2010.11.003
  4. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: Emphasis on risk factors for progression. Br J Haematol. 2007;139(5):730-43. doi: 10.1111/j.1365-2141.2007.06873.x
  5. Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15(1). doi: 10.1038/s41581-018-0077-4
  6. Смирнов А.В., Афанасьев Б.В., Поддубная И.В. и др. Моноклональная гаммапатия ренального значения: консенсус гематологов и нефрологов России по введению нозологии, диагностике и обоснованности клон-ориентированной терапии. Нефрология. 2019;23(6):9-28 [Smirnov AV, Afanasyev BV, Poddubnaya IV, et al. Monoclonal gammopathyof renal signifi cance: Consensus of hematologists and nephrologists of Russia on the establishment of nosology, diagnostic approach and rationale for clone specifi c treatment. Nephrology. 2019;23(6):9-28 (In Russ.)]. doi: 10.36485/1561-6274-2019-23-6-9-28
  7. Steiner N, Göbel G, Suchecki P, et al. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: An observational study of 2935 MGUS patients. Oncotarget. 2018;9(2):2344-56. doi: 10.18632/oncotarget.23412
  8. Bridoux F, Leung N, Hutchison CA, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87(4):698-711. doi: 10.1038/ki.2014.408
  9. Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int. 2018;94(1):178-86. doi: 10.1016/j.kint.2018.01.037
  10. Jain A, Haynes R, Kothari J, et al. Pathophysiology and management of monoclonal gammopathy of renal significance. Blood Adv. 2019;3(15):2409-23. doi: 10.1182/bloodadvances.2019031914
  11. Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86(2):180-6. doi: 10.1002/ajh.21934
  12. Kapoulas S, Raptis V, Papaioannou M. New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies. Nephrol Ther. 2015;11(3):135-43. doi: 10.1016/j.nephro.2014.12.005
  13. Лысенко Л.В., Чеботарева Н.В., Мрыхин Н.Н. и др. Значимость выявления моноклональной гаммапатии у больных нефрологического профиля. Нефрология. 2019;23(2):82-90 [Lysenko LB, Chebotareva NV, Mrykhin NN, et al. Determining of monoclonal gammopathy in nephrological patients. Nephrol. 2019;23(2):82-90 (In Russ.)]. doi: 10.24884/1561-6274-2019-23-2-82-90
  14. Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program. 2012;2012:595-603. doi: 10.1182/asheducation.v2012.1.595.3798563
  15. Knight GB, Gao L, Gragnani L, et al. Detection of WA B cells in HCV infection: A potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies. Arthritis Rheum. 2010;62:2152-9. doi: 10.1002/art.27490
  16. Debiec H, Hanoy M, Francois A, et al. Recurrent membranous nephropathy in an allograft caused by IgG3k targeting the PLA2 receptor. J Am Soc Nephrol. 2012;23(12):1949-54. doi: 10.1681/ASN.2012060577
  17. Said SM, Cosio FG, Valeri AM, et al. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft. Kidney Int. 2018;94(1):159-69. doi: 10.1016/j.kint.2018.01.028
  18. Borza D-B. Autoepitopes and Alloepitopes of Type IV Collagen: Role in the Molecular Pathogenesis of Anti-GBM Antibody Glomerulonephritis. Nephron Exp Nephrol. 2007;106(2):e37-e43. doi: 10.1159/000101791
  19. Dispenzieri A. POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92(8):814-29. doi: 10.1002/ajh.24802
  20. Li W, Lu Z-F, Man X-Y, et al. VEGF upregulates VEGF receptor-2 on human outer root sheath cells and stimulates proliferation through ERK pathway. Mol Biol Rep. 2012;39(9):8687-94. doi: 10.1007/s11033-012-1725-6
  21. Katzmann JA, Kyle RA, Benson J, et al. Screening Panels for Detection of Monoclonal Gammopathies. Clin Chem. 2009;55(8):1517-22. doi: 10.1373/clinchem.2009.126664
  22. Willrich MAV, Murray DL, Kyle RA. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Clin Biochem. 2018;51:38-47. doi: 10.1016/j.clinbiochem.2017.05.001
  23. Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957-9. doi: 10.1182/blood-2009-07-230722
  24. Dasari S, Alexander MP, Vrana JA, et al. DnaJ heat shock protein family B member 9 is a novel biomarker for fibrillary GN. J Am Soc Nephrol. 2018;29(1):51-6. doi: 10.1681/ASN.2017030306
  25. Nasr SH, Vrana JA, Dasari S, et al. DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney Int Reports. 2018;3(1):56-64. doi: 10.1016/j.ekir.2017.07.017
  26. Chauvet S, Frémeaux-Bacchi V, Petitprez F, et al. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood. 2017;129(11):1437-47. doi: 10.1182/blood-2016-08-737163
  27. Hogan JJ, Weiss BM. Bridging the divide: An onco-nephrologic approach to the monoclonal gammopathies of renal significance. Clin J Am Soc Nephrol. 2016;11(9):1681-91. doi: 10.2215/CJN.03160316
  28. Nasr SH, Valeri AM, Cornell LD, et al. Renal Monoclonal Immunoglobulin Deposition Disease: A Report of 64 Patients from a Single Institution. Clin J Am Soc Nephrol. 2012;7(2):231-9. doi: 10.2215/CJN.08640811
  29. Sayed RH, Wechalekar AD, Gilbertson JA, et al. Natural history and outcome of light chain deposition disease. Blood. 2015;126(26):2805-10. doi: 10.1182/blood-2015-07-658872
  30. Gertz MA. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. Am J Hematol. 2018;93(9):1169-80. doi: 10.1002/ajh.25149
  31. Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20(9):2055-64. doi: 10.1681/ASN.2009010110
  32. Sethi S, Fervenza FC, Rajkumar SV. Spectrum of manifestations of monoclonal gammopathy-associated renal lesions. Curr Opin Nephrol Hypertens. 2016;25(2):127-37. doi: 10.1097/MNH.0000000000000201
  33. Bhutani G, Nasr SH, Said SM, et al. Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. Mayo Clin Proc. 2015;90(5):587-96. doi: 10.1016/j.mayocp.2015.01.024
  34. Fermand JP, Bridoux F, Kyle RA, et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood. 2013;122(22):3583-90. doi: 10.1182/blood-2013-05-495929
  35. Kyle RA, Therneau TM, Dispenzieri A, et al. Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenström Macroglobulinemia. Clin Lymphoma, Myeloma Leuk. 2013;13(2):184-6. doi: 10.1016/j.clml.2013.02.005
  36. Sethi S, Rajkumar SV. Monoclonal Gammopathy–Associated Proliferative Glomerulonephritis. Mayo Clin Proc. 2013;88(11):1284-93. doi: 10.1016/j.mayocp.2013.08.002
  37. Milani P, Merlini G, Palladini G. Novel Therapies in Light Chain Amyloidosis. Kidney Int Reports. 2017;3(3):530-41. doi: 10.1016/j.ekir.2017.11.017
  38. Cohen C, Royer B, Javaugue V, et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int. 2015;88(5):1135-43. doi: 10.1038/ki.2015.201
  39. Vaxman I, Gertz M. Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis. Acta Haematol. 2019;141(2):93-106. doi: 10.1159/000495455
  40. Gupta N, Hanley MJ, Xia C, et al. Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. Clin Pharmacokinet. 2019;58(4):431-49. doi: 10.1007/s40262-018-0702-1

Supplementary files

There are no supplementary files to display.

Statistics

Views

Abstract - 49

PDF (Russian) - 10

Cited-By


PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies